|Articles|December 9, 2022

A Changing Horizon for Digital Health Technologies

Digital health platforms, modern delivery models, and edge technologies can transform the way life sciences companies create a virtuous circle of value generation, equipping patients with capabilities that improve health outcomes while providing businesses with valuable data and insights to drive new research, improve stakeholders’ experiences, and accelerate growth. Solutions designed to serve clinical trial participants outside of a clinical setting should be considered as companion services for commercial therapies to drive greater adherence as well as real-world evidence.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related to this article

November 13th, 2026

Pharmaceutical Executive Daily: FDA Shelves CNPV Program

FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.

November 13th, 2026

FDA Pauses Commissioner’s National Priority Voucher Program: Report

FDA Commissioner’s National Priority Voucher program reportedly in limbo for expedited drug reviews.

November 13th, 2026

Eli Lilly Breaks Ground on $3.5 billion Pennsylvania Manufacturing Site

Eli Lilly breaks ground on a $3.5 billion manufacturing facility in Pennsylvania to produce next-generation obesity treatments like retatrutide.

November 13th, 2026

When Small Protocol Decisions Become Enrollment or Retention Barriers

Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.

November 12th, 2026

Pharmaceutical Executive Daily: Moderna Outlines Growth Plan at 2026 Analyst Day

Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth up to $1.5 billion for berobenatide, and Parexel’s Stacy Hurt on how patients’ use of AI is reshaping sponsor communication.

November 12th, 2026

Moderna Lays Out Oncology-Driven Growth Plan at 2026 Analyst Day

Moderna used its 2026 Analyst Day to outline an oncology-driven growth strategy anchored by intismeran and other cancer antigen therapies.

November 12th, 2026

Pfizer and Blackstone Sign Co-Funding Deal for berobenatide

Pfizer and Blackstone Life Sciences sign a co-funding deal in which Blackstone is set to provide up to $1.5 billion through 2028 to advance berobenatide.

November 12th, 2026

How Patients’ Use of AI Impact How Sponsors Communicate with Them

With 60% of Americans using AI health tools, patient advocates are encouraging collaborative use of AI alongside healthcare teams for better outcomes.

A Changing Horizon for Digital Health Technologies

Related to this article

Trending on PharmExec

Eli Lilly Breaks Ground on $3.5 billion Pennsylvania Manufacturing Site

Building Connected AI Ecosystems, Not Standalone Tools

Where AI Is Having the Most Impact and Where Gaps Remain

FDA Pauses Commissioner’s National Priority Voucher Program: Report

Moderna Lays Out Oncology-Driven Growth Plan at 2026 Analyst Day